Supernus Pharmaceuticals, Inc. revised earnings guidance for the full year 2023. For the year, the company expected total revenues to be in the range of $590 million to $610 million compared to previous guidance $580 million to $620 million and Operating loss to be in the range of $15 million to $5 million compared to previous guidance $30 million to $10 million.